{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:16:25Z","timestamp":1786119385496,"version":"build-2736575974"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1097\/hjh.0b013e328332b738","type":"journal-article","created":{"date-parts":[[2009,12,17]],"date-time":"2009-12-17T10:33:20Z","timestamp":1261046000000},"page":"111-118","source":"Crossref","is-referenced-by-count":40,"title":["Angiotensin II signaling via type 2 receptors in a human model of vascular hyporeactivity: implications for hypertension"],"prefix":"10.1097","volume":"28","author":[{"given":"Lorenzo A","family":"Cal\u00f2","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Schiavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Pagnin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Mormino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"D'Angelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achille C","family":"Pessina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-16-20210208","doi-asserted-by":"crossref","first-page":"C82","DOI":"10.1152\/ajpcell.00287.2006","article-title":"Angiotensin II cell signaling. Physiological and pathological effects in the cardiovascular system","volume":"92","author":"Mehta","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"key":"R2-16-20210208","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11906-003-0073-2","article-title":"Role of angiotensin II in regulating vascular structural and functional changes in hypertension","volume":"5","author":"Touyz","year":"2003","journal-title":"Curr Hypertens Rep"},{"key":"R3-16-20210208","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11906-003-0014-0","article-title":"Molecular mechanisms of angiotensin II-induced vascular injury","volume":"5","author":"Ruiz Ortega","year":"2003","journal-title":"Curr Hypertens Rep"},{"key":"R4-16-20210208","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1172\/JCI26384","article-title":"Searching for transcriptional regulators of Ang II-induced vascular pathology","volume":"115","author":"Dzau","year":"2005","journal-title":"J Clin Invest"},{"key":"R5-16-20210208","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0031-6997(24)01434-0","article-title":"Molecular and cellular mechanisms of Ang II-mediated cardiovascular and renal diseases","volume":"52","author":"Kim","year":"2000","journal-title":"Pharmacol Rev"},{"key":"R6-16-20210208","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/01.CIR.0000141573.44737.5A","article-title":"Regression of hypertensive left ventricular hypertrophy by Losartan compared with atenolol. The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Trial","volume":"110","author":"Devereux","year":"2004","journal-title":"Circulation"},{"key":"R7-16-20210208","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/ajh.2008.16","article-title":"Left ventricular hypertrophy and clinical outcomes in hypertensive patients","volume":"21","author":"Ruilope","year":"2008","journal-title":"Am J Hypertens"},{"key":"R8-16-20210208","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/08037050510034185","article-title":"Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy","volume":"14","author":"Olsen","year":"2005","journal-title":"Blood Press"},{"key":"R9-16-20210208","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1161\/01.CIR.103.7.919","article-title":"SECURE Investigators. Effects of ramipril and vitamin E on atherosclerosis: the Study to Evaluate Carotid Ultrasound Changes in Patients Treated With Ramipril and Vitamin E (SECURE)","volume":"103","author":"Lonn","year":"2001","journal-title":"Circulation"},{"key":"R10-16-20210208","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1097\/00004872-200308000-00001","article-title":"Angiotensin II AT2 receptor subtype: an uprising frontier in cardiovascular diseases?","volume":"21","author":"Volpe","year":"2003","journal-title":"J Hypertens"},{"key":"R11-16-20210208","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1161\/01.CIR.101.14.1653","article-title":"Correction of arterial structure and endothelial dysfunction in humans essential hypertension by the angiotensin receptor antagonist losartan","volume":"101","author":"Schiffrin","year":"2000","journal-title":"Circulation"},{"key":"R12-16-20210208","first-page":"1","article-title":"Signal transduction from the angiotensin II AT2 receptor","volume":"11","author":"Nouet","year":"2000","journal-title":"TEM"},{"key":"R13-16-20210208","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000076752","article-title":"Bartter's and Gitelman's syndromes: from gene to clinic","volume":"96","author":"Naesens","year":"2004","journal-title":"Nephron Physiol"},{"key":"R14-16-20210208","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/sj.ki.5000253","article-title":"Vascular tone control in humans: the utility of studies in Bartter's\/Gitelman's syndromes","volume":"69","author":"Cal\u00f2","year":"2006","journal-title":"Kidney Int"},{"key":"R15-16-20210208","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/00151642-200512010-00004","article-title":"Angiotensin II signaling in the Bartter's and Gitelman's syndromes, a negative human model of hypertension","volume":"12","author":"Cal\u00f2","year":"2005","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"R16-16-20210208","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/HJH.0b013e328010d4d2","article-title":"RhoA\/Rho-kinase pathway: much more than just a modulation of vascular tone. Evidence from studies in humans","volume":"25","author":"Cal\u00f2","year":"2007","journal-title":"J Hypertens"},{"key":"R17-16-20210208","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1093\/ndt\/gfn118","article-title":"Absence of vascular remodelling in a high angiotensin-II state (Bartter's and Gitelman's syndromes): implications for angiotensin II signalling pathways","volume":"23","author":"Cal\u00f2","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R19-16-20210208","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0092-8674(93)90383-2","article-title":"MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo","volume":"75","author":"Sun","year":"1993","journal-title":"Cell"},{"key":"R20-16-20210208","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1074\/jbc.272.2.1368","article-title":"The Dual Specificity mitogen-activated protein kinase phosphatase 1 and 2 are induced by the p42\/p44MAPK cascade","volume":"272","author":"Brondello","year":"1997","journal-title":"J Biol Chem"},{"key":"R21-16-20210208","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1126\/science.286.5449.2514","article-title":"Reduced MAP kinase phosphatase-1 degradation after p42\/p44MAPK-dependent phosphorylation","volume":"286","author":"Brondello","year":"1999","journal-title":"Science"},{"key":"R22-16-20210208","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1097\/HJH.0b013e3282f60d98","article-title":"Silencing regulator of G protein signaling-2 (RGS-2) increases angiotensin II signaling: insights into hypertension from findings in Bartter's\/Gitelman's syndromes","volume":"26","author":"Cal\u00f2","year":"2008","journal-title":"J Hypertens"},{"key":"R23-16-20210208","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1097\/01.hjh.0000226202.80689.8f","article-title":"Reduced expression of regulator of G protein signaling-2 in hypertensive patients increases calcium mobilization and ERK1\/2 phosphorylation induced by angiotensin II","volume":"24","author":"Semplicini","year":"2006","journal-title":"J Hypertens"},{"key":"R24-16-20210208","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1210\/jc.2004-0498","article-title":"Increased expression of regulator of G protein signaling\u20132 (RGS-2) in Bartter's\/Gitelman's sydrome. A role in the control of vascular tone and implication for hypertension","volume":"89","author":"Cal\u00f2","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R25-16-20210208","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1161\/01.RES.87.9.753","article-title":"Functional reconstitution of the angiotensin II type 2 receptor and Gi activation","volume":"87","author":"Hansen","year":"2000","journal-title":"Circ Res"},{"key":"R26-16-20210208","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1097\/01.hjh.0000166845.49850.39","article-title":"Negative regulation of Rho\/Rho kinase by angiotensin II type 2 receptor in vascular smooth muscle cells: role in angiotensin II-induced vasodilation in stroke-prone spontaneously hypertensive rats","volume":"23","author":"Savoia","year":"2005","journal-title":"J Hypertens"},{"key":"R27-16-20210208","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S0272-6386(96)90514-4","article-title":"Increased urinary NO2 \u2212\/NO3 \u2212 and cyclic GMP levels in patients with Bartter's syndrome: relationship to vascular reactivity","volume":"27","author":"Cal\u00f2","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"R28-16-20210208","first-page":"12","article-title":"Increased endothelial nitric oxide synthase mRNA level in Bartter's and Gitelman's syndrome. Relationship to vascular reactivity","volume":"51","author":"Cal\u00f2","year":"1999","journal-title":"Clin Nephrol"},{"key":"R29-16-20210208","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1097\/00004872-200410000-00019","article-title":"Rho kinase and PAI-1 in Bartter's\/Gitelman's syndromes: relationship to angiotensin II signaling","volume":"22","author":"Pagnin","year":"2004","journal-title":"J Hypertens"},{"key":"R30-16-20210208","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.amjhyper.2005.03.747","article-title":"Reduced mRNA and protein content of Rho guanine nucleotide exchange factor (RhoGEF) in Bartter's and Gitelman's syndromes. Relevance for the pathophysiology of hypertension","volume":"18","author":"Pagnin","year":"2005","journal-title":"Am J Hypertens"},{"key":"R31-16-20210208","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1161\/01.HYP.0000050101.90932.14","article-title":"Cardiac angiotensin II type 2 receptor activates the kinin\/NO system and inhibits fibrosis","volume":"41","author":"Kurisu","year":"2003","journal-title":"Hypertension"},{"key":"R32-16-20210208","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2337\/diacare.29.02.06.dc05-2048","article-title":"Insulin signaling, glucose metabolism and the angiotensin II signaling system. Studies in Bartter's\/Gitelman's syndromes","volume":"29","author":"Davis","year":"2006","journal-title":"Diabetes Care"},{"key":"R33-16-20210208","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/sj.jhh.1002231","article-title":"Urinary albumin excretion, endothelial dysfunction and cardiovascular risk: study in Bartter's\/Gitelman's syndromes and relevance for hypertension","volume":"21","author":"Cal\u00f2","year":"2007","journal-title":"J Hum Hypertens"},{"key":"R34-16-20210208","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1161\/01.HYP.0000228997.88162.a8","article-title":"Angiotensin II type 2 receptor bradykinin B2 receptor functional heterodimerization","volume":"48","author":"Abadir","year":"2006","journal-title":"Hypertension"},{"key":"R35-16-20210208","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coph.2006.11.007","article-title":"Regulators of G protein signaling: a spotlight on emerging functions in the cardiovascular system","volume":"7","author":"Wieland","year":"2007","journal-title":"Curr Opin Pharmacol"},{"key":"R36-16-20210208","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1172\/JCI200317836","article-title":"RGS2. a \u2018turn-off\u2019 in hypertension","volume":"111","author":"Le","year":"2003","journal-title":"J Clin Invest"},{"key":"R37-16-20210208","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.peptides.2005.03.010","article-title":"The AT2 receptor: a matter of love and hate","volume":"26","author":"Steckelings","year":"2005","journal-title":"Peptides"},{"key":"R38-16-20210208","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1046\/j.1523-1755.2001.060003882.x","article-title":"Abnormalities of Gq-mediated cell signaling in Bartter and Gitelman syndromes","volume":"60","author":"Cal\u00f2","year":"2001","journal-title":"Kidney Int"},{"key":"R39-16-20210208","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1046\/j.1523-1755.2002.00128.x","article-title":"Reduced content of alpha subunit of Gq protein in monocytes of Bartter and Gitelman syndromes: relationship with vascular hyporeactivity","volume":"61","author":"Cal\u00f2","year":"2002","journal-title":"Kidney Int"},{"key":"R40-16-20210208","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/ndt\/gfg204","article-title":"Oxidative stress related factors in Bartter's and Gitelman's syndromes: relevance for angiotensin II signalling","volume":"18","author":"Cal\u00f2","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"R41-16-20210208","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1097\/00004872-199816070-00014","article-title":"Reduced susceptibility of low density lipoprotein to oxidation in patients with overproduction of nitric oxide (Bartter's and Gitelman's syndrome)","volume":"16","author":"Cal\u00f2","year":"1998","journal-title":"J Hypertens"},{"key":"R42-16-20210208","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s11906-008-0050-x","article-title":"Evidence for benefits of angiotensin receptor blockade beyond blood pressure control","volume":"10","author":"Siragy","year":"2008","journal-title":"Curr Hypertens Rep"}],"container-title":["Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00004872-201001000-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:11:36Z","timestamp":1786039896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004872-201001000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/hjh.0b013e328332b738","relation":{},"ISSN":["0263-6352"],"issn-type":[{"value":"0263-6352","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}